Abstract
OBJECTIVE: This study aimed to evaluate and compare the serum levels of CTRP9, CTRP15, HOMA-IR, and HOMA-B in metabolic syndrome patients, with and without coexisting coronary artery disease. METHODOLOGY: This was a cross-sectional comparative study involving two groups, each with 40 patients. Group-A comprised metabolic syndrome patients with coronary artery disease, whereas Group-B included metabolic syndrome patients without coronary artery disease. The study was carried out from September 20(th), 2019 to August 31(st), 2020 at Department of Physiology & Cell Biology, University of Health Sciences, Lahore. After getting written informed consent clinical and biochemical characteristics of the patients were assessed. Data analysis was conducted with IBM SPSS version 26. RESULTS: The systolic (p=0.012) as well as diastolic (p=0.001) blood pressure and serum low-density lipoprotein cholesterol (p=0.032) was significantly higher in the Group-A when compared with the Group-B. Serum high-density lipoprotein was significantly lower (p = 0.031) in Group-A compared to Group-B. Significantly elevated levels of HOMA-IR (p=0.001), and CTRP15 (p=0.001) were present in Group-A as compared to the Group-B. A statistically significant negative correlation was observed between HOMA-B and CTRP15 serum levels (rho=-0.356, p=0.024) in Group-A. CONCLUSION: In this study, decreased insulin secretion was found to correlate with increased CTRP15 levels in patients with metabolic syndrome and coronary artery disease. This finding suggests the potential role of CTRP15 in the pathophysiology of beta cell dysfunction possibly reflecting either a state of CTRP15 resistance or a compensatory response to impaired insulin secretion.